Skip to content

Flow Pharma

Request correction

Corporate brand

Unclaimed

Flow Pharma is a Cleveland, Ohio based biopharmaceutical company dedicated to immunotherapy innovation, developing T-cell stimulating therapeutic peptides for cancer and viral diseases.

Last updated September 1, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Flow Pharma, Inc. is a Cleveland, Ohio based biopharmaceutical company. The company utilizes artificial intelligence to detect peptide targets on cancer cells and virus-infected cells, then designs, synthesizes, and delivers identical peptides to stimulate therapeutic attack by the patient's native immune system. Its product portfolio includes FLOVID-20 for COVID-19, FlowVax for Ebola/Marburg, FlowVax BreastCA for triple-negative breast cancer, and FlowVax HPV for HPV-induced cancers. The company recently completed pre-clinical testing of FLOVID-20 at the United States National Laboratory at the University of Texas in Galveston, demonstrating that FLOVID-20 immunized macaque monkeys, protecting them from COVID-19.

History

Flow Pharma, Inc. is a Cleveland, Ohio based biopharmaceutical company. The company utilizes artificial intelligence to detect peptide targets on cancer cells and virus-infected cells, then designs, synthesizes, and delivers identical peptides to stimulate therapeutic attack by the patient's native immune system. It recently completed pre-clinical testing of FLOVID-20, a COVID-19 immunotherapy, at the United States National Laboratory at the University of Texas in Galveston. The test results demonstrate that FLOVID-20 immunized macaque monkeys, protecting them from COVID-19. Flow Pharma has created FlowVax Survivin, a breast cancer immuno-therapeutic, targeting a neoantigen found on malignant breast cells. Its additional cancer therapeutic development targets include HPV-related cancers of the cervix and head & neck.

Products and positioning

  • FLOVID-20

    An inhaled or injected treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations.

  • FlowVax Ebola/Marburg

    By stimulating T-cells to target these viruses, long-lasting infection prevention is attainable.

  • FlowVax BreastCA

    A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.

  • FlowVax HPV

    A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/flow-pharma-united-states · Editorial policy · How profiles are compiled